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Abstract
 Synaptic dopamine (DA) release induced by amphetamine or otherRationale:
experimental manipulations can displace [ C]raclopride (RAC*) from
dopamine D2-like receptors. We hypothesized that exogenous levodopa might
increase dopamine release at striatal synapses under some conditions but not
others, allowing a more naturalistic assessment of presynaptic dopaminergic
function. Presynaptic dopaminergic abnormalities have been reported in
Tourette syndrome (TS).
 Test whether levodopa induces measurable synaptic DA release inObjective:
healthy people at rest, and gather pilot data in TS.
 This double-blind crossover study used RAC* and positron emissionMethods:
tomography (PET) to measure synaptic dopamine release 4 times in each of 10
carbidopa-pretreated, neuroleptic-naïve adults: before and during an infusion of
levodopa on one day and placebo on another (in random order). Five subjects
had TS and 5 were matched controls. RAC* binding potential (BP ) was
quantified in predefined anatomical volumes of interest (VOIs). A separate
analysis compared BP  voxel by voxel over the entire brain.
 DA release declined between the first and second scan of each dayResults:
(p=0.012), including on the placebo day. Levodopa did not significantly reduce
striatal RAC* binding and striatal binding did not differ significantly between TS
and control groups. However, levodopa’s effect on DA release differed
significantly in a right midbrain region (p=0.002, corrected), where levodopa
displaced RAC* by 59% in control subjects but  BP  by 74% in TSincreased
subjects.
 Decreased DA release on the second scan of the day isDiscussion:
consistent with the few previous studies with a similar design, and may indicate
habituation to study procedures. We hypothesize that mesostriatal DA neurons
fire relatively little while subjects rest, possibly explaining the non-significant
effect of levodopa on striatal RAC* binding. The modest sample size argues for
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effect of levodopa on striatal RAC* binding. The modest sample size argues for
caution in interpreting the group difference in midbrain DA release with
levodopa.
 This article is included in the channel.Tics 
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Introduction
Dopamine (DA) release from neurons has often been conceptual-
ized as occurring via two separable mechanisms: tonic, referring 
to low levels of DA in extrasynaptic spaces that may be more 
accessible to microdialysis, and phasic, referring to synaptic DA 
release at synapses following presynaptic action potentials1. Pha-
sic dopamine release is crucial to dopamine’s role in changing 
behavior2, including in learning sequences of movements3. Normal 
tonic dopamine release but abnormal phasic dopamine release has 
been postulated to occur in several disease states, including drug 
abuse4 and Tourette syndrome (TS)5–8.
The radioligand [11C]raclopride (hereinafter RAC*) binds to 
dopamine D2-like (D2, D3 and D4) receptors loosely enough to be 
displaced by physiological increases of dopamine at the synapse. 
This property has been exploited to detect changes in synaptic 
DA release induced by experimental manipulations including the 
administration of amphetamine9. However, amphetamine also has 
some disadvantages in this context—primarily, that it does not really 
produce phasic dopamine release in the usual, temporal, sense of 
the word. Rather, it causes prolonged, substantial dopamine release 
regardless of environmental demands. Scientific questions about 
DA release in the absence of amphetamine might be better tested 
with a pharmacological stimulus that could potentially increase 
the magnitude of DA release, but under tighter endogenous con-
trol. Additionally, amphetamine can induce symptomatic effects 
including euphoria10 and transiently increased tic severity11; these 
effects can themselves alter brain activity, complicating interpre-
tation of the results. Ideally, a pharmacological challenge drug to 
test phasic dopamine release would not produce effects noticed by 
the subject.
The present study provides preliminary data for a novel approach 
to testing presynaptic dopamine release using levodopa, the body’s 
natural synthetic precursor to dopamine. Exogenous levodopa 
boosts dopamine synthesis almost immediately in both parkinso-
nian and healthy brains [reviewed in 12]. The extra dopamine is rap-
idly released at the synapse in people with DA deficiency13, and 
there is evidence that this happens also in the non-parkinsonian 
brain. In people, including in people with tics, levodopa produces 
dose-dependent yawning, mild sleepiness, and effects on working 
memory—i.e., CNS-mediated effects14–16. Additional evidence for 
levodopa-induced synaptic DA release in the non-parkinsonian 
brain is reviewed in 12. When given after an adequate dose of carbi-
dopa, which prevents conversion to dopamine but does not cross the 
blood-brain barrier, systemic levodopa administration essentially 
delivers dopamine selectively to the brain, as confirmed by the 
fact that it does not alter quantitative whole-brain blood flow17–19, 
as dopamine would if it were being delivered systemically or pro-
duced outside the brain. In fact, with adequate carbidopa pretreat-
ment, volunteers usually cannot tell whether they are receiving 
levodopa or a placebo12,16.
We used PET and RAC* to measure synaptic dopamine release 
in response to a standardized levodopa infusion (after carbidopa) 
in 10 subjects. Since no previous data were available on levodopa 
effects on RAC* PET, we included before- and during-levodopa 
RAC* PET scans as well as before- and during-placebo scans. Half 
of the subjects had a chronic tic disorder and the other half were 
matched control subjects without tics, to generate preliminary data 
in each population. The original hypotheses were that levodopa 
would stimulate striatal dopamine production in the controls, but 
may affect people with TS differently.
Methods
Participants
This study was approved by the Human Studies Committee of 
Washington University School of Medicine (IRB, protocol # 03-0347, 
the WUSM Radioactive Drug Research Committee (protocol # 
497F), and the U.S. Food and Drug Administration (Investigator 
IND #69,745 for i.v. levodopa). All subjects provided written con-
firmation of informed consent before study participation.
Diagnostic assessment included psychiatric and neurological exam-
ination by a movement-disorders-trained neuropsychiatrist (KJB) 
and a validated semistandardized psychiatric diagnostic interview 
[SCID-IV; 20]. Tic subjects met DSM-IV-TR criteria for Tourette’s 
Disorder. Control subjects with no history of tics were matched 
one-to-one for age, sex and handedness (with one ambidextrous 
TS subject matched to a right-handed control). Exclusion criteria 
included any lifetime neurological or Axis I psychiatric disorder 
(except that TS, ADHD and OCD were allowed in tic subjects, and 
migraine and specific phobia were allowed in either group), current 
serious general medical illness, medication history of dopamine 
antagonists or other drugs likely to affect the dopaminergic system, 
current use of any neuroactive medication, lactation, possibility of 
pregnancy, or contraindication to levodopa or MRI.
Clinical features were characterized by the Diagnostic Confidence 
Index (0=no features of TS; 100=all enumerated features of classic 
TS; scores in the original clinical validation sample ranged from 5 
to 100, mean=61, S.D.=20)21; the YGTSS, an expert-rated measure 
of tic severity over the previous week (motor tic scale 0–25, vocal 
tic scale 0–25, impairment scale 0–50, higher scores indicating a 
higher symptom burden)22,23; the revised Tic Symptom Self-Report 
(TSSR) scale, a self-report scale including scores of 0–3 for each 
of 18 motor tics and 16 vocal tics, with 3 indicating tics were “very 
frequent and very forceful” over the preceding two weeks24,25; the 
ADHD Rating Scale, an expert-rated measure of current severity of 
Attention-Deficit/Hyperactivity Disorder (ADHD) based on DSM-
IV criteria (range 0–54, higher scores indicating a higher symp-
tom burden)26; and the Y BOCS, an expert-rated measure of current 
obsessive-compulsive disorder (OCD) severity (range 0–40, higher 
scores indicating a higher symptom burden)27,28.
Overview of subject participation
Each subject had 4 RAC* PET scans: two scans on each of two days 
at least a week apart (Figure 1). After oral carbidopa and the base-
line PET scan, an infusion of levodopa or saline placebo was begun 
by vein at an individualized dose intended to produce a steady-
state levodopa plasma concentration of 600ng/mL. After allowing 
30 minutes to approach steady-state levodopa concentration, a sec-
ond scan was done while the infusion continued. The order (levo-
dopa on day 1 and placebo on day 2, or the reverse) was assigned 
randomly to each subject, and subjects and PET staff were blind to 
drug assignment during all scans.
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The room was darkened and subjects were instructed to lie quietly 
in the scanner with eyes closed throughout each scan. Study staff 
asked subjects every 5 or 10 minutes if they were comfortable and 
made sure they were awake.
Levodopa infusion
Subjects took 200mg carbidopa by mouth at least 1 hour before lev-
odopa infusion began. A dose of levodopa estimated to fill each sub-
ject’s volume of distribution at a target concentration of 600ng/mL 
was infused over 10 minutes, followed until the second PET scan 
of the day was completed by a maintenance infusion at a rate esti-
mated to compensate for elimination. In prior work, these infusion 
rates produced a mean blood level across subjects of ~625ng/mL 
after 25 minutes of infusion16. On average, that concentration pro-
duces substantial motor benefit in early Parkinson disease29,30, yet 
this infusion method is well enough tolerated that subjects cannot 
reliably distinguish the levodopa and saline infusions12,16.
Levodopa plasma concentration
Levodopa plasma concentration was measured by a validated 
method31.
Radiotracer preparation
[11C]raclopride was prepared by O-[11C]methylation of (S)-O- 
desmethylraclopride HBr (ABX Advanced Biochemical Com-
pounds, Radeberg, Germany) using a modification of previously 
reported procedures32,33. Carbon-11 was produced as 11CO2 using the 
Washington University JSW BC 16/8 cyclotron and the 14N(p,α)11C 
nuclear reaction. The 11CO2 was converted to 11CH3I using the micro-
processor-controlled PETtrace MeI MicroLab (GE Medical 
Systems, Milwaukee, WI), and immediately used for [11C]methylation 
of (S)-O-desmethylraclopride. Product [11C]raclopride was puri-
fied via semipreparative HPLC, and reformulated in a 10% ethanol/
normal saline solution. The radiochemical purity exceeded 95%, 
and the specific activity exceeded 500 Ci/mmol, as determined 
by analytical HPLC. The mass of raclopride was ≤13.9 µg per 
injected dose.
Image acquisition
RAC* was given i.v. over an interval of 30 seconds (median dose 
14.8mCi, interquartile range 11.0–18.9mCi). PET images were 
acquired on a Siemens ECAT 961 camera beginning with arrival of 
radiotracer in the head and continuing for 60 minutes using image 
frames of increasing duration. An MP-RAGE sequence was used 
to acquire a 3-dimensional T1-weighted image of the brain with 
acquisition time ~400 sec and voxel dimensions 1.25×1×1mm3.
Image alignment
The PET images were realigned within each subject and then to 
the subject’s MRI using a rigid-body alignment method with low 
measured error, optimized for dynamic PET images34–37.
VOI analysis
Nine subcortical volumes of interest (VOIs) were defined for 
each subject from that subject’s MRI by a high-dimensional semi-
automated method of known high test-retest reliability38 (Figure 2). 
These VOIs corresponded to the thalamus and the left and right 
putamen, caudate, nucleus accumbens, and globus pallidus. An 
additional VOI was created from the average (weighted by region 
volume) of 22 FreeSurfer-labeled gray matter regions comprising 
frontal cortex (11 left- and 11 right-hemisphere VOIs). This large 
frontal VOI produced adequate counting statistics for modest noise 
in the time-activity curve (Figure 3). A cerebellum VOI was traced 
on each subject’s MR image. All VOIs were transferred to each 
subject’s realigned PET images using the optimized MRI-to-PET 
transformation matrix computed in the alignment step. The cerebel-
lar VOI was trimmed if needed so that no voxel in the VOI corre-
sponded to any of the inferior-most four slices in any frame of that 
subject’s original PET images. Thus in each subject each VOI was 
identical for all four PET scans.
The binding potential BPND39,40, an estimate of the quotient Bmax/KD, 
was computed as one less than the distribution volume ratio (DVR), 
which was derived for each of the nine subcortical VOIs and the 
frontal lobe VOI using the cerebellar reference region41. As we had 
no a priori hypothesis about laterality of results in any of the paired 
basal ganglia nuclei, we averaged corresponding left and right 
BPNDs (weighted by VOI volume) to produce for each PET scan six 
Figure 1. Study overview. 
Figure 2. Automated striatal VOIs. Atlas-based VOI outlines are 
shown on an axial section from one subject (Cd yellow, Pu light blue, 
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Figure 3. Time-activity curves. Decay-corrected time-activity curves are shown for the right putamen (filled circles), the frontal lobe VOI (+’s), 
and the cerebellar reference region (empty circles) from one subject’s pre-levodopa PET scan.
final BPND values, one each for frontal lobe cortex (FL), thalamus 
(Th), putamen (Pu), caudate (Cd), nucleus accumbens (NA), and 
globus pallidus (Pl).
The primary statistical analysis used a repeated-measures analysis 
of variance (rmANOVA) with BPND as dependent variable, diag-
nosis (tic or control) as a between-group variable, time (before or 
during the infusion) and day (placebo or levodopa) as within- 
subject variables, and region (the six VOI-based BPNDs) as a repeated 
measure. Exploratory analyses used an ANOVA for each region.
Whole-brain analysis
For each subject, a DVR image was computed using at each voxel 
in the brain the Logan graphical method with the cerebellar VOI 
described in the preceding section as reference region41. As a meth-
ods check, the mean across striatal VOIs of the voxelwise DVR 
value was essentially identical to the regional DVR computed using 
the standard methods described above. Analysis was limited to vox-
els in atlas space at which every subject contributed data from all 
frames of the dynamic PET acquisition.
Whole-brain comparisons used voxelwise t tests corrected for mul-
tiple comparisons in SPM 8, as follows. A t test compared DVR 
images between the TS and the control group, and clusters of con-
tiguous voxels with t exceeding the threshold corresponding to 
p<0.001 were accepted as significantly different between groups 
if cluster volume exceeded the threshold required to control False 
Discovery Rate (FDR) for the entire dataset at p<0.05.
Two comparisons were made, one based on mean baseline DVR 
images and the other based on levodopa effect ΔDVR images. Each 
subject’s two pre-infusion RAC* PET scans, one from each scan 
day, were averaged to create that subject’s mean baseline DVR 
image. The difference of the during-levodopa DVR image and the 
during-placebo DVR image in a subject was used to create that sub-
ject’s levodopa effect ΔDVR image.
Results
Subjects
Subject characteristics and adequacy of matching are reported in 
Table 1, and clinical characteristics of the TS group are reported 
in Table 2.
Levodopa levels
Levodopa plasma concentrations were ~800–1000ng/ml before the 
RAC* scan and ~500–700ng/ml after the RAC* scan, and did not 
differ significantly between groups (Table 3).
Table 1. Subject characteristics and adequacy of matching.
Measure Tic Subjects (N=5)
Controls 
(N=5)
Age (years; mean ± S.D.) 33.8 ± 12.9 32.8 ± 11.1
Sex, male (N) 4 4
Race, Caucasian (N) 4 4
Handedness, right (N) 4 3
OCD diagnosis (N) 1 0
ADHD diagnosis (N) 2 0
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Counting statistics in VOIs at baseline
The a priori VOIs showed higher and more reliable binding in 
striatum and pallidum, as expected. Nevertheless, the thalamus, 
GP and frontal cortex VOIs also produced good counting statistics 
(Figure 3). For every one of the VOIs the baseline BPND estimates 
were positive in all 120 scans, and were very similar between the 
two scan days (Table 4, Figure 4).
Table 4. RAC* binding in a priori VOIs at baseline. 
VOI FL Th Pl NA Cd Pu
BPND (mean) 0.15 0.32 1.11 1.80 2.13 2.79
BPND (standard 
deviation) 0.05 0.08 0.20 0.30 0.45 0.42
BPND values > 0 
(of 20 scans) 20 20 20 20 20 20
p for mean > 0 




.70 .63 .88 .76 .94 .96
p for correlation 
(8 df, 1 tail) .012 .025 .0003 .005 .0000 .0000
Abbreviations: FL, frontal lobes; Th, thalamus; Pl, pallidum; NA, nucleus 
accumbens; Cd, caudate; Pu, putamen.
Table 2. Clinical characteristics of the Tourette syndrome 
group. The Y BOCS was completed for only 1 tic subject; the 
score was 9 on day 1 and 14 on day 2. 
Scale Scores  (mean ± S.D.)
DCI score 36.8 ± 22.0
YGTSS 
Motor tic score 10.6 ± 3.4
Vocal tic score 7.8 ± 4.0
Impairment score 9.4 ± 9.8
TSSR score
Motor 9.3 ± 5.9
Vocal 3.2 ± 2.3
Total 12.5 ± 7.9
ADHD Rating Scale 11.6 ± 10.7
Abbreviations: DCI=Tourette Syndrome Diagnostic Confidence 
Index, YGTSS=Yale Global Tic Severity Scale, Y-BOCS=Yale-Brown 
Obsessive Compulsive Scale, ADHD=Attention Deficit Hyperactivity 
Disorder, TSSR=Tic Symptom Self Report.
Table 3. Levodopa plasma concentrations in ng/ml, mean ± SD.
Time Controls Tic subjects p (t test)
Peak (10' into 
infusion) 1591.5 ± 232.5 1938.8 ± 726.3 0.36
Just before 
RAC* scan 788.0 ± 152.4 992.4 ± 322.9 0.26
Just after 
RAC* scan 529.5 ± 149.2 662.8 ± 136.1 0.21
Figure 4. Stability of baseline binding between scan days in the a priori VOIs. BPNDs from the first scan of each day are plotted for all 10 
subjects, with the BPND from the pre-placebo scan on the horizontal axis and from the pre-levodopa scan on the vertical axis. For the paired 
VOIs the mean of the left and right BPND is used. The diagonal line is the line of identity. The inset shows an enlarged view of the data from the 
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Figure 5. Change in BPND on the placebo day. For each of the a priori VOIs, mean BPND across all 10 subjects is shown before and during 
the infusion on the placebo day only. Error bars show SD. Numeric labels are p values for the main effect of time in the individual region 
ANOVAs (putamen p=.115).
Stability of RAC* binding between days and with time
This study includes a before- and after-infusion scan on each of two 
days. On one day the infusion contains levodopa, and on the other 
day it is a saline placebo. Thus each subject has three non-levodopa 
scans (the first scan of each day plus the scan during the placebo 
infusion). As expected, BPND was quite reproducible in the two pre-
levodopa scans (correlated at r = 0.99 across VOI and subject).
To our surprise, BPND increased between the 1st and 2nd scan of 
the day (main effect of time, F=10.605, df=1,8, p=0.012), and this 
change did not differ significantly between the levodopa and pla-
cebo days (time × day interaction, F=0.014, df=5,4, p=0.909). In 
other words, the two scans on the placebo day were not identical. 
Mean BPND was 2.7% to 24.0% higher during the placebo infusion, 
indicating decreased dopamine release compared to earlier on the 
same day. The change from the first to the second scan of each day 
was significant in most individual region analyses: main effect of 
time, thalamus p=0.002, frontal lobe p=0.032, caudate p=0.039, pal-
lidum p=0.048, and nucleus accumbens p=0.052 (multivariate time 
× region interaction F=4.173, df=5,4, p=0.096). Figure 5 shows the 
BPND for each VOI from both scans on the placebo day only.
Effect of levodopa on RAC* binding
Since the pre- and on-placebo scans differed, the appropriate com-
parison for the on-levodopa RAC* scan is the on-placebo scan. 
Therefore we assessed the effect of levodopa by comparing the 
BPND in the on-LD and on-placebo scans. In the VOI analysis, there 
was no significant effect of LD (day × time interaction, F=0.014, 
df=1,8, p=0.909).
Comparison of RAC* binding between TS and control groups
TS vs control at baseline. For the ANCOVA across all regions, 
RAC* binding did not differ significantly between tic and control 
subjects (main effect of diagnosis, F=0.744, df=1,8, p=0.413; tic 
vs control). Nevertheless, baseline RAC* binding was numerically 
higher in TS by 13–17% in the three striatal VOIs and by 5–7% in 
the frontal lobe and thalamus VOIs. The whole-brain analysis iden-
tified no significant regional differences in baseline RAC* binding 
between TS and control subjects.
TS vs control: time effect (change from first to second scan). 
There was a trend for the change in BPND during the infusion to 
be smaller in tic subjects (time × diagnosis interaction F=4.211, 
df=1,8, p=0.074). Each of the three striatal regions showed a similar 
effect when analyzed individually (0.05 < p < 0.10). Figure 6 shows 
the VOI BPND values before and during the placebo infusion, by 
diagnosis.
TS vs control: effect of levodopa on RAC* binding. In the a priori 
VOIs, the effect of LD did not differ overall in tic subjects (day 
× time × diagnosis interaction, F=1.308, df=1,8, p=0.286), and 
the 4-way interaction (day × time × diagnosis × region) was not 
significant (F=1.577, df=5,4, p=0.340). Although not statistically 
significant, pallidal and thalamic BPND tended to decrease in con-
trol subjects but increase in the tic subjects (Figure 7).
The whole-brain analysis identified a similar but statistically sig-
nificant effect in two clusters, where RAC* binding decreased 
with levodopa in controls, consistent with increased dopamine 
release during the levodopa infusion, but RAC* binding increased 
in the TS group. The first cluster included 38 voxels in midbrain 
(1.0 ml, FDR corrected p=0.002), with a peak t value of 9.0 
(8 df) at atlas coordinate (1.5, −21, −15) and extending laterally 
in approximately the right substantia nigra/ventral tegmental area 
(Figure 8a). A second significant cluster of 19 voxels (0.5 ml, cor-
rected p=0.023) occurred in parahippocampal gyrus, with peak 
t=7.92 at (22.5, −39, −6) (Figure 8b). The mean change in BPND 
with levodopa in these regions is shown in Figure 8c. In both these 
clusters, the BPND on placebo was positive in all subjects (p < 0.001, 
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Figure 6. Change in [11C]raclopride binding on placebo day, by diagnosis. Mean BPNDs from the a priori VOIs, before and during the 
infusion on the placebo day only. Error bars show SD. The p values shown are for the time × diagnosis interaction in the individual region 
ANOVAs.
Figure 7. Levodopa-induced change in BPND, by diagnosis. Mean BPND for the a priori VOIs is shown during the levodopa and placebo 
infusions; the error bar indicates SD. The day × time × diagnosis interaction and the day × time × diagnosis × region interaction were not 
significant. The daggers indicate a trend in the thalamic and pallidal VOIs for BPND to decrease with levodopa in the control group but 
increase with levodopa in the tic group (regional ANOVA, day × time × diagnosis interaction, pallidum p=0.050, thalamus p=0.098).
The highest t value in the whole-brain comparison, 11.62, occurred 
in Brodmann’s area 13, but the cluster volume was only 0.1 ml, not 
significant by FDR correction (Figure 8d).
Discussion
Change in striatal BPND on the placebo day
BPND increased from before to during the placebo infusion in the 
striatum, thalamus and frontal lobe VOIs, especially in control 
subjects (Figure 5, Figure 6). Surprisingly little information 
describes within-day stability of RAC* binding, though several 
studies compare binding across time intervals of days to months42–45. 
Mawlawi et al.46 scanned 10 subjects twice each on the same day 
using a bolus-plus-constant-infusion method, and found no sig-
nificant mean change from the first to the second scan. However, 
Alakurtti and colleagues47 found that mean BPND increased from the 
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Figure 8. RAC* binding on levodopa vs. placebo, by diagnosis. Differences in the RAC* binding response to levodopa between TS and 
control subjects, thresholded at uncorrected p = 0.001, in color, laid over the MRI template image in grayscale. a, b: Significant clusters, with 
blue lines crossing at the peak t value in midbrain (a, three views) and in parahippocampal gyrus (b). A third statistically significant cluster 
was centered at the posterior edge of the occipital lobe, but both the location and the observation that in this cluster the BPND on placebo was 
negative in half the subjects suggests that this cluster likely does not reflect specific binding. c: Levodopa-induced change in BPND, TS vs. 
control, in the clusters shown in A and B. R., Right; PHG, parahippocampal gyrus. Asterisks indicate that mean BPND differs significantly from 
zero. d: The blue lines cross at the voxel with the highest t value in the whole-brain SPM analysis of levodopa effect ΔDVR images (t=11.62, 8 df).
with the change (about +5%) reaching statistical significance in 
medial and lateral thalamus.
The observation in the present study that BPND increased from the 
first to second scan of the day is consistent with this background, 
and is relevant to RAC* challenge PET studies in general, because 
essentially all such studies use a before- vs. after-intervention 
design. Slifstein et al. [48, p. 357] argue that the existence of pla-
cebo-induced DA responses make the before-after model more 
appropriate for amphetamine challenge studies. However, our 
results and those of Alakurtti et al.47 suggest that BPND increases 
from the first to the second scan even without active intervention. 
This does not invalidate the results of most before-after RAC* stud-
ies, since amphetamine challenge decreases striatal RAC* BPND by 
a large fraction, and to a lesser extent so do many cognitive and 
behavioral interventions in such studies, including studies of the 
placebo effect. However, the present results suggest that before-
after RAC* studies may be less sensitive to manipulations that 
would decrease dopamine release.
Possible pathophysiological interpretation. The increase in BPND 
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of time rather than a placebo effect per se, especially as placebo 
administration is more likely to increase dopamine release48–50. The 
presumed decrease in dopamine release during the placebo infusion 
could indicate that control subjects accommodate to the scanner 
environment over the course of the study day.
Effect of levodopa infusion on RAC* binding
Levodopa effect on RAC* binding in striatum. Striatal RAC* binding 
was not substantially changed by levodopa. Initially this result came 
as a surprise to the authors, because levodopa was given expressly 
with the expectation that it would increase synaptic dopamine lev-
els. Briefly, support for this expectation includes the following. 
First, in Parkinson disease there is overwhelming evidence both by 
clinical observations and by RAC* PET imaging that exogenous 
levodopa substantially increases striatal dopamine release51–53. But 
there is also evidence in subjects without dopamine deficiency: 
intravenous levodopa is rapidly taken up from the bloodstream into 
the brain and converted into dopamine, and several studies show 
that it then boosts synaptic dopamine release [reviewed in 12]. For 
instance, exogenous levodopa produces clear sedative and cognitive 
effects in healthy people54–56. Thus the authors originally expected 
that exogenous levodopa would decrease striatal RAC* binding.
However, further reflection and reading have motivated a differ-
ent view whereby the results support the original goal of choos-
ing a pharmacological challenge agent that would stimulate phasic 
dopamine release, but under endogenous control. Recall that the 
concern with stimulants as challenge agents was that they cause a 
substantial release of dopamine at the striatal synapse regardless 
of current environmental demands; this approach may produce 
a ceiling effect for dopamine release that does not reflect typical 
endogenous control. A sensible hypothesis to explain the results of 
the present study would be that a research subject lying awake in 
a quiet, darkened room without specific cognitive demands has no 
need for substantial phasic release of dopamine, and thus even if 
exogenous levodopa has added dopamine to presynaptic vesicles, 
they are not released at a substantial rate at the synapse. A levodopa-
raclopride study of a motor task in healthy individuals provides 
direct experimental support of this hypothesis57. That study was 
properly designed with two sessions, placebo on one day and levo-
dopa on another, with randomized order. Levodopa increased stri-
atal dopamine release during performance of a motor task, but not 
at rest. Since in the present study all subjects were at rest during all 
scans, the results are consistent with those of Flöel and colleagues57.
TS and control group comparisons
The tic and control subgroups have only five subjects each, and 
differences between the tic and control groups in the a priori VOIs 
were not statistically significant, so there is little need to comment 
further on these results. Previous drafts of this report included such 
discussion58.
The whole-brain analysis comparing RAC* binding with levo-
dopa vs. placebo did identify statistically significant differences 
(Figure 8a–c). In midbrain (approximately substantia nigra/VTA) 
and in parahippocampal gyrus, levodopa stimulated dopamine 
release in controls but reduced it in TS subjects in. A similar pat-
tern, though not statistically significant, was observed in orbital 
cortex (Brodmann’s area 13), thalamus and globus pallidus (Figure 7 
and Figure 8d).
One expects exogenous levodopa to increase dopamine release in 
the substantia nigra, as occurred in the control subjects. D2 and D3 
dopamine receptors are present in the substantia nigra and their 
activation inhibits spike firing, dopamine synthesis and dopamine 
release by nigral dopaminergic cells59. We hypothesize that levo-
dopa increased dopamine stimulation of these inhibitory D2-like 
receptors in control subjects, and this may have prevented levo-
dopa from stimulating nigrostriatal dopamine release into the 
striatum.
Subjects with TS, however, showed an increase in substantia nigra 
RAC* binding with levodopa, consistent with a decrease in nigral 
dopamine release. Nigral dopamine release has been related to 
reward and novelty in humans. Healthy adults with higher novelty 
seeking scores had lower D2-like binding ([18F]fallypride) in SN, 
consistent with greater dopamine release60. Functional MRI studies 
have also demonstrated substantia nigra signal related to stimulus 
novelty or to the Novelty Seeking trait61–63. Healthy adults receiving 
a sweet vs salty taste had BOLD activation in this region64. Despite 
this information, it is not clear how to relate a decrease in levodopa-
stimulated dopamine release in substantia nigra to the pathophysi-
ology of TS. Explaining the similar difference in nigral levodopa 
response in TS in parahippocampal gyrus and orbital cortex is no 
easier, though dopaminergic effects on D2-like binding in hippoc-
ampus have been documented in Parkinson disease65 and dopamine 
agonists evoke changes in orbital cortex activity66. The trend for 
a similar effect in thalamus is consistent with a [11C]FLB-457 
PET study in which amphetamine provoked thalamic dopamine 
release in control subjects but not in TS67. Overall, these results 
are consistent with an abnormality of presynaptic dopaminergic 
pharmacology in TS, but the limitations of this comparison must 
be acknowledged.
Limitations
Higher-affinity radioligands, such as [18F]fallypride or [11C]FLB 
457, have advantages for measuring cortical D2Rs, e.g. in the fron-
tal lobe where D2Rs appear at much lower concentrations than in 
the striatum. There are two primary concerns with RAC* outside 
the striatum [reviewed thoroughly in 9]. The first concern is a reli-
ability issue: since the concentration of D2-like receptors is low 
in cortex compared to striatum, the counting statistics are poor for 
cortical VOIs of similar volume, and this renders the computed 
BPNDs suspect. For instance, some regional RAC* BPNDs are neg-
ative or close enough to zero that displacement studies produce 
results that are hard to interpret. In the present study, FreeSurfer-
defined cortical regions allowed the creation of a large, reliably 
defined frontal lobe VOI, in which PET time-activity curves were 
low in noise (Figure 3), allowing statistically reliable estimates of 
BPND that were uniformly positive (Table 4, Figure 4). Similarly 
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RAC* displacement in thalamus has shown adequate counting 
statistics and reliability in previous studies47,68.
The second concern with RAC* in extrastriatal regions is one of 
validity or interpretation. RAC* binding in cortex includes some 
nonspecific binding33, so a fair question is to what extent specific 
binding in cortex represents dopamine D2-like receptors. D2 and 
D4 receptors are expressed in human prefrontal cortex, though at 
relatively low concentrations compared to striatum69. On the other 
hand, at least one study’s results suggest that raclopride may have 
superior sensitivity to fallypride for measuring dopamine release in 
some cortical regions70. The validity concern is less worrisome in 
human thalamus, which contains predominantly D3 rather than D2 
receptors71, and in substantia nigra, where D2 and D3 receptors are 
well characterized. Other authors have interpreted substantia nigra 
RAC* displacement as indicating synaptic dopamine release9.
Finally, comparing TS and control subgroups of only five subjects 
each provides insufficient power to identify some true group dif-
ferences (type II error). More importantly, the small sample size 
lowers confidence in how representative the statistically significant 
differences are of the overall population of adults with TS.
Future directions
These results suggest that a natural next step for research in TS is 
to test whether dopamine release in TS differs during a dopamine-
releasing cognitive (or other) task. Levodopa may augment the 
task-evoked release or interact with it differently in people with 
versus without tics. Along these lines, a cognitive-pharmacological 
interaction fMRI study in TS found that LD changed the BOLD 
responses to a working memory task72. A newer levodopa infusion 
method produced roughly twice as high a levodopa plasma concen-
tration as the infusion used in this study12, and may produce greater 
dopamine release.
Dataset 1. PET images and clinical data
http://dx.doi.org/10.5256/f1000research.5672.d42172 
The spreadsheet in OpenDocument file format provides the clinical 
data and links each PET scan to the subject scanned and the 
condition (i.e., before or during the placebo or levodopa infusion). 
Also 40 PET files are provided with the filename extension .v, one 
for each dynamic PET scan. These files are in ECAT file format; 
users of other imaging file formats will find useful information at 
the following web site: http://www.turkupetcentre.net/petanalysis/
format_image_ecat.html
Data availability
F1000Research: Dataset 1. PET images and clinical data, 10.5256/
f1000research.5672.d4217274
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 Lars Nyberg
Umeå Center for Functional Brain Imaging, Umeå, Sweden
The most novel aspect of the study was the investigation of levodopa. This is very interesting. No
significant levodopa effects were, however, observed. The authors offer some interesting thoughts on the
reason for this null effect, most critically pointing to a need to have an active task PET design. This is a
plausible argument that may stimulate further research on this topic.
A potentially interesting methodological contribution is the observation of a difference between the 1  and
2  scan on each day of scanning.
The study is likely underpowered, in particular for any group comparison (5 TS, 5 ctrls), so the
repeated-measures analysis was most likely not very sensitive. I would treat the observed differences
between TS and control groups from the whole-brain analysis as preliminary.
I may have missed it, but I could not find information about how the PET scans were reconstructed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response (  ) 24 Mar 2015F1000Research Advisory Board Member
, Department of Psychiatry, Washington University in St. Louis, USAKevin J Black
The authors thank Prof. Nyberg for the thoughtful review. 
The [ C]raclopride PET data were collected in 3D mode and reconstructed on the Siemens ECAT
961 scanner console using filtered backprojection (ramp filter), with attenuation measured before
each emission scan using an external Ge/ Ga source.
We agree with all the reviewers that the between-group comparison is useful primarily as pilot data
because of the small group sizes. 
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 W.R. Wayne Martin
Division of Neurology, University of Alberta, Edmonton, AB, Canada
This is a carefully performed study that presents a novel approach to measure presynaptic dopamine
release using the administration of exogenous levodopa, coupled with raclopride PET scanning.
Preliminary data are provided using this method in a small group of controls and subjects with Tourette
syndrome. 
The authors describe a decline in dopamine release in striatum, thalamus and frontal lobe between the
first and second scan of each day in response to placebo administration in normal subjects, possibly due
to habituation to study procedures. Levodopa administration did not alter striatal dopamine release
differently in Tourette syndrome vs. controls. However, dopamine release differed significantly in the
midbrain and parahippocampal gyrus in the two conditions. Levodopa stimulated dopamine release in
controls but reduced it in Tourette subjects.
Although these are important observations, the number of subjects studied was small. Hence, these must
be considered pilot data although they are consistent with a rather complex dopaminergic role in Tourette
syndrome. Of interest for future studies would be the evaluation of task-evoked dopamine release in
response to cognitive tasks. Lastly, the observation that habituation occurs in response to placebo
infusions has important implications to the interpretation of placebo-controlled studies of dopamine
release.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 17 March 2015Referee Report
doi:10.5256/f1000research.6062.r7601
 Marie Vidailhet
Department of Research of Technology and Development, Hôpital Pitié Salpêtrière, Paris, France
The authors studies the raclopride binding (displacement) in groups of subjects (normal and Tourette
syndrome). They studied the effect of levodopa infusions and of a placebo. The subjects were studied at
rest.
Basically, they found that in Tourette syndrome, dopamine release was smaller  (reduced) than in
controls, in midbrain (approximately substantia nigra/VTA) and in parahippocampal gyrus.
 
This is an interesting paper and the methodology is adequate. The subjects are studied at rest, this may
underestimate the dynamic of dopamine release and it would have be more interesting to study this
phenomenon during a task. The groups are very small, and the effect in Tourette syndrome may also be
different according to the characteristics of the patient (with or without additional behavioral disorders).
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phenomenon during a task. The groups are very small, and the effect in Tourette syndrome may also be
different according to the characteristics of the patient (with or without additional behavioral disorders).
Nevetherless, the study is consistent with the presence of abnormality of presynaptic dopaminergic
pharmacology in Tourette syndrome.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Discuss this Article
Version 1
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, Department of Psychiatry, Washington University in St. Louis, USAKevin J Black
In reviewing structural MR studies of TS, I noticed that reported increasedGarraux and colleagues (2006) 
gray matter volume in midbrain from a voxel-based morphometry study of symptomatic adults with TS.
Their midbrain region included approximately STN/VTA. Their finding needs replication and does not
explain our results, but the identification of midbrain is interesting.
 No competing interests were disclosed.Competing Interests:
Author Response (  ) 04 Jun 2015F1000Research Advisory Board Member
, Department of Psychiatry, Washington University in St. Louis, USAKevin J Black
Regarding the change in striatal [ C]raclopride binding from the first to the second scan on the placebo
day (first paragraph of Discussion and Figures 5 and 6), I inadvertently omitted citations to two additional
studies that also support the present results. 
 reported same-day test-retest values for striatal [ C]raclopride binding, usingDewey (1992)et al, 
cerebellum as a reference region, in 6 experiments in 3 baboons. BP  can be calculated from the values
given in Table 1. Mean ± SD striatal BP  was 2.012 ± 0.148 on the first scan of the day and 2.180 ±
0.207 on the second (mean change 8.4%, p=0.026 by paired t test using N=6, following the authors'
analysis; alternatively, collapsing replicate measurements across days to the first- and second-scan
means for each subject, 0.1<p<0.2 by unpaired t test, N=3). 
 reported test-retest results using a different paradigm in which 7 young healthyWang (1999, Table 1)et al. 
adult human volunteers were studied twice on each of two days, 1-2 weeks apart. The first scan on each
day followed injection of a saline placebo, and the 2nd scan of each day followed injection of
methylphenidate 0.5mg/kg. Comparing the second to the first placebo scans, mean ± SD striatal BP
 increased from 2.768 ± 0.437 to 2.973 ± 0.442 (mean change 7.8%, p=0.032 by paired t test).
The study by Dewey and colleagues provides additional same-day test-retest data consistent with our
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results (compare also refs. 46 and 47 above). The Wang  study, which could have been cited withet al.
refs. 42-45 above, shows a similar test-retest increase in striatal [ C]raclopride binding over a period of
1-2 weeks, again consistent with a small decrease in synaptic dopamine concentration from the first to
second scan.
 No competing interests were disclosed.Competing Interests:
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We thank Professors Vidailhet and Martin for their thoughtful comments.
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